GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) researchers have developed a STING agonist that can be delivered systemically as opposed to intratumorally, which can overcome challenges of accessing hard to reach tumors or cancers that have
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) researchers have developed a STING agonist that can be delivered systemically as opposed to intratumorally, which can overcome challenges of accessing hard to reach tumors or cancers that have